Skip to main content


Pressmeddelande   •   Mar 01, 2006 15:28 CET

At the request of Apotex and Dr Reddy’s Laboratories, citing scheduling
conflicts for their legal counsels, the U.S. District Court for the Southern District of New York has
rescheduled the trial date for the Plavix® patent litigation originally set for April 3, 2006.

The new
date is June 12, 2006, though the Court indicated that the date may be later, depending on the duration
of the trial of another, earlier case. Sanofi-aventis and Bristol-Myers Squibb did not object to the
defendants’ request to reset the trial date.

Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are statements that are not historical facts. These
statements include financial projections and estimates and their underlying assumptions, statements
regarding plans, objectives and expectations with respect to future operations, products and services,
and statements regarding future performance. Forward-looking statements are generally identified
by the words “expect,” “anticipates,” “believes,” “intends,” “estimates,” “plans” and similar
expressions. Although sanofi-aventis’ management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that forward-looking information
and statements are subject to various risks and uncertainties, many of which are difficult to predict
and generally beyond the control of sanofi-aventis, that could cause actual results and developments
to differ materially from those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include those discussed or identified in the
public filings with the SEC and the AMF made by sanofi-aventis, including those listed under “Risk
Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in sanofi-aventis’
annual report on Form 20-F for the year ended December 31, 2004. Other than as required by
applicable law, sanofi-aventis does not undertake any obligation to update or revise any forwardlooking
information or statements.

Bifogade filer